Links: -Youtube: https://t.co/w0jSEoeSRU -Spotify: https://t.co/P6puorGEhI -Apple:

4️⃣ And that’s what keeps him going: “That’s what makes this venture very interesting.”

🚨 NEW EPISODE 🚨 Nanobiotix $NBTX has officially joined France’s biotech billion-dollar club — alongside Abivax $ABVX and Medincell $MEDCL Here’s why this Paris-based company could be on the verge of something big 👇

RECORDING: just talked with Thomas, who is leading one of the best biotechs in Europe (@valnevaSE). Amazing story, big impact 🦠 #BIOEurope $VLA $VALN

-Youtube: https://t.co/J5NwImNMD2 -Spotify: https://t.co/Q350oUsDjk -Apple:

EPISODE: Why do so many CAR-T cell therapies fail in clinical trials? A lack of knowledge of how they bind with cancer cells, says the Dutch startup @LUMICKS_nl. Co-founder and Head of Product Gerrit Sitters tells me how the company spun out of academia, and how its technology

-Youtube: https://t.co/eyarlqBfOe -Spotify: https://t.co/tQubHIFcFd -Apple:

EPISODE: Pharming famously produces its rare disease drug RUCONEST via transgenic rabbits 🐰 But its pipeline now goes far beyond this. “I've been very impressed that they didn't rest on their laurels” after RUCONEST, says newcomer CEO Fabrice Chouraqui. “They kept being very

Friday night recording with Laurent from Nanobiotix, now a billion-dollar biotech 🇫🇷 $NBTX $NANO

-Youtube: https://t.co/ORdOyLEw5o -Spotify: https://t.co/y7iIQ42GN9 -Apple:

EPISODE: Raising a $60M Series C in 2025 is tough. Daniela just did it to bring a breakthrough tissue therapeutic to the market! The funding round is a testament to the fact that “when there is a good product with good science and a clear unmet need...it is possible to find the

-Youtube: https://t.co/Ez5uKFXLcs -Spotify: https://t.co/9bRrO5SB1B -Apple:

Thanks Jon Yu for helping making it happen🙏

EPISODE: In 2019, @ArarisBiotech🇨🇭 was founded. Earlier this year, it was acquired in one of Europe’s biggest-ever preclinical deals — $400M upfront! Even though this was CEO @DGrabulovski’s second high-profile exit after Covagen in 2014, he still found entrepreneurship far from

RECORDING: New tools are reshaping biotech. LUMICKS’ (@LUMICKS_nl) single-cell affinity data are changing cell therapy and biologics. Great to meet Gerrit, who cofounded the company in Amsterdam 🇳🇱 in 2014 right after his PhD. Full episode drops end of October ⏰

Thanks Jeito for the intro 🙏

-Youtube: https://t.co/TGxX98OfuS -Spotify: https://t.co/N7QnSbdQU9 -Apple:

EPISODE (40 🥳): Azafaros 🇳🇱🇨🇭 raised a massive $147M Series B round in May. The surprising part? It didn’t even need US investors! “This testifies to the fact that Europe is finally playing a big role in this type of environment…To me, that’s great news,” says CEO Stefano

-Youtube: https://t.co/P8YWIpuqNO -Spotify: https://t.co/mLZPEr1wxO -Apple:

NEW EPISODE: The longevity space is full of failed treatments, but Insilico delivered positive Phase 2 data last year. And it was an AI-generated drug. “Over the past 12 years, we've seen dozens of very promising [anti-aging] companies that collapsed,” says Alex Zhavoronkov